Ibrutinib dose modification and effectiveness in Japanese patients with chronic lymphocytic leukemia: a post-hoc analysis of the Orbit study

The Orbit study confirmed safety and effectiveness of ibrutinib in Japanese patients with treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL). This post-hoc analysis evaluated ibrutinib treatment patterns and impact of dose modifications, stratifying patients into three subgroups: (1) continuous full-dose (420 mg/day); (2) initially full-dose then discontinued and restarted; (3) reduced starting dose. Dose modifications after resumption in subgroup 2 were mainly due to adverse events (78.5%), and reduced starting doses in subgroup 3 were mainly due to adverse event concerns (79.7%). In subgroup 3, 89.2% experienced dose modification and 32.3% increased to 420 mg/day. Mean relative dose intensity was higher in subgroup 1 than 2/3 (92.5% vs 73.8%/48.1%). The 36-month progression-free survival (PFS)/overall survival rates were 67.9%/88.3%, 75.9%/89.2%, and 86.0%/86.5%, respectively. Subgroups 1 and 3 mainly included biologically unfavorable diseases and elderly vulnerable patients, respectively. Individualized ibrutinib dosing may be effective in maintaining CLL treatment even in real-world practice.

Authors

Institutions

Publication Details

Journal
Leukemia & lymphoma/Leukemia and lymphoma
Published
2026-11-17
DOI
https://doi.org/10.1080/10428194.2026.2746183
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ibrutinib dose modification and effectiveness in Japanese patients with chronic lymphocytic leukemia: a post-hoc analysis of the Orbit study

Nobuyuki Aotsuka, Ai Omi, Kazuhiro Shibayama, Tsuyoshi Muta et al.
2 links
Leukemia & lymphoma/Leukemia and lymphoma
Chronic Lymphocytic Leukemia Research
article

Ibrutinib dose modification and effectiveness in Japanese patients with chronic lymphocytic leukemia: a post-hoc analysis of the Orbit study

Nobuyuki Aotsuka, Ai Omi, Kazuhiro Shibayama, Tsuyoshi Muta, Takuro Yoshimura, Shingo Kurahashi, Shuichi Ota, Takahiro Kumode, Hideto Tamura, Yoshihiro Kameoka, Yuma Fujimori, Yosuke Masamoto, Eri Matsuki, Jun Takizawa, Yasushi Isobe, Hirokazu Nagai, Naoki Takahashi, Kensuke Kojima, Go Yamamoto, Sadao Aoki, Junji Suzumiya, Kazutaka Ozeki, Takanori Toyama
article en

Abstract

The Orbit study confirmed safety and effectiveness of ibrutinib in Japanese patients with treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL). This post-hoc analysis evaluated ibrutinib treatment patterns and impact of dose modifications, stratifying patients into three subgroups: (1) continuous full-dose (420 mg/day); (2) initially full-dose then discontinued and restarted; (3) reduced starting dose. Dose modifications after resumption in subgroup 2 were mainly due to adverse events (78.5%), and reduced starting doses in subgroup 3 were mainly due to adverse event concerns (79.7%). In subgroup 3, 89.2% experienced dose modification and 32.3% increased to 420 mg/day. Mean relative dose intensity was higher in subgroup 1 than 2/3 (92.5% vs 73.8%/48.1%). The 36-month progression-free survival (PFS)/overall survival rates were 67.9%/88.3%, 75.9%/89.2%, and 86.0%/86.5%, respectively. Subgroups 1 and 3 mainly included biologically unfavorable diseases and elderly vulnerable patients, respectively. Individualized ibrutinib dosing may be effective in maintaining CLL treatment even in real-world practice.

Leukemia & lymphoma/Leukemia and lymphoma
Dokkyo University (JP), Niigata University of Pharmacy and Medical and Life Sciences (JP), University of Kochi (JP), Akita University (JP), Keio University (JP), Konan Kosei Hospital (JP), Fukuoka University Hospital (JP), Kindai University Hospital (JP), Osaka City General Hospital (JP), Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital (JP), University of Tokyo Hospital (JP), Sapporo Hokuyu Hospital (JP), Saitama International Medical Center (JP), Akita Red Cross Hospital (JP), Japanese Red Cross Narita Hospital (JP), Dokkyo Medical University Saitama Medical Center (JP), Toyohashi Municipal Hospital (JP), Nagoya Medical Center (JP), Johnson & Johnson (Brazil) (BR), Toranomon Hospital (JP), Miyazaki Prefectural NOBEOKA Hospital (JP), Johnson & Johnson K.K. (Japan) (JP), Niigata University (JP), Kōchi University (JP), Nippon Medical School (JP), Saitama Medical University (JP)
Good health and well-being
Chronic Lymphocytic Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon